cell.com· Kotaro Nomura, Tomoyo Fukami, Shinichiro Kato, Shunya Tanaka, Akito Fukuda, Yuki Koike, Masaki Kondo, Kazuhiro Kumagai, Takuma Irie, Genki Okumura, Tetsuro Taki, Shingo Sakashita, Masayuki Shirasawa, Tatsuya Yoshida, Kouya Shiraishi, Ryo Ariyasu, Yuki Takeyasu, Takahiro Niimi, Tetsuya Sakai, Masahiro Torasawa, Hiroaki Kanemura, Shin Saito, Takuo Hayashi, Akinori Kanai, Kazuya Takamochi, Tomohiro Haruki, Keiju Aokage, Hitomi Nishinakamura, Shohei Koyama, Genichiro Ishii, Yutaka Suzuki, Yasushi Goto, Makoto Nishio, Kenji Suzuki, Yasuhiro Tsutani, Yasushi Yatabe, Hiroyuki Mano, Masahiro Tsuboi, Shogo Kumagai, Hiroyoshi Nishikawa·· 19 hours agoPickScore67
Lung neuroendocrine cancer induces immunosuppressive macrophages via serotonin to drive resistance to the T cell engager tarlatamab
In brief
Nomura et al. found that lung neuroendocrine cancer shapes immunosuppressive macrophages through tumor-derived serotonin via the HTR7 pathway, mediating resistance to tarlatamab and ICB. This neuroimmune mechanism holds in both SCLC and LCNEC, and points to HTR7 as a potentially druggable therapeutic vulnerability.
Why it matters
It defines a mechanism by which tumor-derived serotonin via HTR7 undermines T cell responses to tarlatamab and ICB in lung neuroendocrine cancer.
Source: cell.com · cell.com